1 / 21

MEDICAL INTERNET NEWS

MEDICAL INTERNET NEWS. MEDIC 5 28/03/2019. Common acid reflux medications linked to increased kidney disease risk Date: February 19, 2019 Source: University of California - San Diego.

dwana
Download Presentation

MEDICAL INTERNET NEWS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MEDICAL INTERNET NEWS MEDIC 5 28/03/2019

  2. Common acid reflux medications linked to increased kidney disease risk Date: February 19, 2019 Source: University of California - San Diego Mining a large database of adverse reactions to medications, UC San Diego researchers found that people who took proton pump inhibitors (PPIs) for heartburn and acid reflux were more likely to experience kidney disease than people who took other forms of antacid The research team focused on patientswho took PPIs and no other medications, narrowing their study population down to approximately 43,000 patients. They applied a mathematical algorithm to look for statistically significant differences in reported kidney-related complications between patients who took PPIs and the control group, approximately8,000 patientswho took histamine-2 receptor blockers, such as Zantac or Pepcid, and no other medications.

  3. Common acid reflux medications linked to increased kidney disease risk Date: February 19, 2019 Source: University of California - San Diego Here's what they found: Patients who took only PPIs reported a kidney-related adverse reaction at a frequency of 5.6 percent, compared to 0.7 percent for patients who took only histamine-2 receptor antagonists. Drilling down, the team found that, compared to the control group, patients who took only PPIs were 28.4 times more likely to report chronic kidney disease, as well as acute kidney injury(4.2 times more likely), end-stage renal disease(35.5 times more likely) and unspecified kidney impairment(8 times more likely). Patients who took PPIs were also more likely to experience electrolyte abnormalities.

  4. TREMFYA One-Press Patient Controlled Injector Approved for Plaque Psoriasis FEBRUARY 27TH, 2019   EDITORSDERMATOLOGY, MEDICINE Janssen Pharma, a part of Johnson & Johnson, won FDA approval for its TREMFYA One-Press single-dose injector. The device is used to deliver TREMFYA (guselkumab)as a treatment for moderate to severe plaque psoriasis. The needle is completely hidden and only comes out when the device is placed against the skin and activated. Physicians are expected to teach patients how to use the TREMFYA One-Press, and once everyone is satisfied, patients can do the injections themselves, something that’s required to be performed once every two months.

  5. TREMFYA One-Press Patient Controlled Injector Approved for Plaque Psoriasis FEBRUARY 27TH, 2019   EDITORSDERMATOLOGY, MEDICINE The efficacy and safety of TREMFYA administered with One-Press in patients with moderate-to-severe plaque psoriasis was also evaluated in the double-blind, placebo-controlled ORION study. In the study, a greater proportion of patients in the TREMFYA group achieved an IGA score of 0 or 1 or a Psoriasis Area and Severity Index (PASI 90) response at week 16 (81 percent and 76 percent, respectively) than in the placebo group (0 percent for both endpoints).

  6. TREMFYA One-Press Patient Controlled Injector Approved for Plaque Psoriasis FEBRUARY 27TH, 2019   EDITORSDERMATOLOGY, MEDICINE The proportion of patients who achieved anIGA score of 0 at week 16 was higher in the TREMFYA group compared to the placebo group (56 percent vs. 0 percent). The proportion of patients who achieved aPASI 100response at week 16 was higher in the TREMFYA group compared to the placebo group(50 percent vs. 0 percent). The majority of injection-site reaction symptoms with One-Press were mild and transient in nature.

  7. FDA Approves Expanded Uses for Type 2 Diabetes Drugs Miriam E. Tucker - March 01, 2019 AstraZenecaannounced FDA's approval of the sodium-glucose cotransporter type 2 (SGLT2) inhibitordapagliflozin(Farxiga) and dapagliflozin + metforminextended release (Xigduo XR) for use in patients with type 2 diabetes and moderate renal impairment, defined as chronic kidney disease with an estimated glomerular filtration rate [eGFR] of 45-59 mL/min/1.73 m2. The previous label had restricted use of the medication to patients with eGFR 60 mL/min/1.73m2 and above.

  8. FDA Approves Expanded Uses for Type 2 Diabetes Drugs Miriam E. Tucker - March 01, 2019 Approval for the new indication is based on results of the 24-weekDERIVEstudy of 321 patients with inadequately controlled type 2 diabetes and eGFR 45-59 mL/min/1.73m2. Dapagliflozin alone or combined with metformin is still not recommended when eGFR is less than 45 mL/min/1.73m2 and remains contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) or end-stage renal disease, or on dialysis.

  9. Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC Published Online: 5:55 PM, Fri March 8, 2019 An accelerated approval has been granted by the FDA for the combination of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) as a frontline treatment for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).The approval is based on the phase III IMpassion130 trial, in which the addition of the PD-L1 inhibitor atezolizumab to nab-paclitaxel reduced the risk of progression or death by 40% compared with nab-paclitaxel alone in this patient population.

  10. Atezolizumab/Nab-Paclitaxel Approved by the FDA for PD-L1+ TNBC Published Online: 5:55 PM, Fri March 8, 2019 “The FDA approval of this Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic triple-negative breast cancer, a disease with high unmet medical need,” Sandra Horning, MD, chief medical officer and head of global product development, Genentech (Roche), said in a statement. “ThisTecentriqcombination is the first cancer immunotherapy regimen to be approved in breast cancer, representing a meaningful step forward in the understanding of this disease.”

  11. Lowering blood pressure prevents worsening brain damage in elderly Date: March 18, 2019 Source: American College of Cardiology Elderly people with high blood pressure, or hypertension, who took medicine to keep their 24-hour systolic blood pressure around 130 mm Hg for three years showed significantly less accumulation of harmful brain lesions compared with those taking medicine to maintain a systolic blood pressure around 145 mm Hg, according to research presented at the American College of Cardiology's 68th Annual Scientific Session The trial enrolled199 people who were an average age of 81 years old. All participants had hypertension at the start of the trial, with an average systolic blood pressure around 150 mm Hg, as well as evidence of some cerebrovascular disease on an MRI scan. Half of the participants were randomly assigned to receive standard blood pressure control and half were assigned to receive more intensive blood pressure control.

  12. Lowering blood pressure prevents worsening brain damage in elderly Date: March 18, 2019 Source: American College of Cardiology After three years, those maintaining the lower systolic blood pressure level had about a 40 percent relative reduction in the accumulation of the white matter lesions, the study's first co-primary endpoint, than those with higher blood pressure. "The average 80-year-old without a major illness such as cancer or heart failure can expect to live about 13 more years, and if you cut back the accrual of vascular damage over the course of that timeframe it could substantially improve a person's quality of life, Intensive blood pressure control also brought cardiovascular benefits.

  13. Tramadol Linked to Higher Mortality in Osteoarthritis Janis C. Kelly - March 12, 2019 FindingsIn this cohort study that included 88 902 patients with osteoarthritis, initial prescription of tramadolwas associated with a significantly increased risk of mortality over 1 year compared with initial prescription of naproxen(hazard ratio [HR], 1.71), diclofenac (HR, 1.88), celecoxib (HR, 1.70), and etoricoxib (HR, 2.04), but not compared with codeine (HR, 0.94). MeaningTramadol prescription may be associated with increased all-cause mortality compared with commonly prescribed nonsteroidal anti-inflammatory drugs, but further research is needed to determine if this relationship is causal.

  14. FDA Approves Atezolizumab Combination for Initial Treatment of Adults With ES-SCLC MARCH 19, 2019 Officials with the FDA have approvedatezolizumab (Tecentriq, Genentech) in combination with carboplatin and etoposide (chemotherapy), for the firstline treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).“Tecentriqis the first cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer, which is especially difficult to treat,” said Sandra Horning, MD, chief medical officer and head of Global Product Development for Genentech, in a prepared statement. “Until now, there have been limited treatment advances for this disease, and we are excited to bring a potential new standard of care to patients that has been shown to improve survival compared to chemotherapy.”

  15. FDA Approves Atezolizumab Combination for Initial Treatment of Adults With ES-SCLC MARCH 19, 2019 According to Genentech, a member of the Roche Group, this approval is based on results from the Phase III IMpower133 study, which showed that atezolizumab in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone (median overall survival [OS] = 12.3 versus 10.3 months; hazard ratio [HR] = 0.70, 95 percent CI: 0.54-0.91; p=0.0069) in the intention-to-treat (ITT) population. The atezolizumab-based combination also significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to chemotherapy alone (PFS=5.2 versus 4.3 months; HR=0.77; 95 percent CI: 0.62-0.96; p=0.017).

  16. Dapagliflozin Offers Benefits for Diabetes Patients With Heart Failure Conferences > American College of Cardiology 2019 – Published on: March 18, 2019Mary Caffrey New findings for the type 2 diabetes (T2D) drug dapagliflozinshow it offers benefits to a wide spectrum of patients with heart failure, and it may reduce death for those with a high-risk condition called reduced ejection fraction.The results, drawn from the 17,000-person study DECLARE, show that the sodium glucose cotransporter 2 (SGLT2) inhibitor reduced hospitalization for patients with heart failure with and without reduced ejection fraction, but the benefits emerged earlier for those with reduced ejection fraction (HFrEF).

  17. Dapagliflozin Offers Benefits for Diabetes Patients With Heart Failure Conferences > American College of Cardiology 2019 – Published on: March 18, 2019Mary Caffrey • The findings were presented Monday at the 68th Scientific Session of the American College of Cardiology (ACC) meeting in New Orleans, Louisiana • Patients with HFrEF who tookdapagliflozin saw the composite of cardiovascular death and HHF drop by 38% compared with placebo. • Patients with HFrEF saw rates of cardiovascular death fall by 45% and death from any cause fall by 41% after taking dapagliflozin, compared with placebo. • .

  18. Semaglutide Plus SGLT-2 Inhibitor Reduces HbA1c, Body Weight By Reuters Staff - March 20, 2019 NEW YORK (Reuters Health) - Semaglutide is an effective add-on treatment for patients whose type 2 diabetes is not well controlled on sodium-glucose cotransporter-2 (SGLT-2) inhibitors, new research shows. Patients on SGLT-2s randomized to the once-weekly glucagon-like peptide-1 (GLP-1) analog had a significantly greater improvement in glycemic control and lost more weight than those assigned to placebo, Dr. Bernard Zinman of Mount Sinai Hospital in Toronto and colleagues found. "The addition of semaglutide 1.0 mg appears to be an effective, well tolerated option for patients who have not met their therapeutic goals despite treatment with an SGLT-2 inhibitor," they conclude in The Lancet Diabetes & Endocrinology, online March 1.

  19. Semaglutide Plus SGLT-2 Inhibitor Reduces HbA1c, Body Weight By Reuters Staff - March 20, 2019 In the SUSTAIN 9 trial, type 2 diabetes patients with HbA1c levels of 7% to 10% despite being on an SGLT-2 inhibitor for at least 90 days were randomly assigned to semaglutide or placebo for 30 weeks. Most patients (71.5%) were also taking metformin, and 12.9% were on a sulfonylurea. HbA1c was reduced by 1.42% and body weight by 3.81 kg, on average, with semaglutide compared with placebo.

More Related